- Home
- LUNR vs IBRX Comparison
LUNR vs IBRX Comparison
Compare LUNR & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUNR
- IBRX
- Stock Information
- Founded
- LUNR 2013
- IBRX 2014
- Country
- LUNR United States
- IBRX United States
- Employees
- LUNR N/A
- IBRX N/A
- Industry
- LUNR Industrial Machinery/Components
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LUNR Industrials
- IBRX Health Care
- Exchange
- LUNR Nasdaq
- IBRX Nasdaq
- Market Cap
- LUNR 1.7B
- IBRX 1.9B
- IPO Year
- LUNR N/A
- IBRX N/A
- Fundamental
- Price
- LUNR $18.08
- IBRX $3.42
- Analyst Decision
- LUNR Strong Buy
- IBRX Strong Buy
- Analyst Count
- LUNR 6
- IBRX 3
- Target Price
- LUNR $15.83
- IBRX $13.58
- AVG Volume (30 Days)
- LUNR 12.7M
- IBRX 6.0M
- Earning Date
- LUNR 03-20-2025
- IBRX 03-18-2025
- Dividend Yield
- LUNR N/A
- IBRX N/A
- EPS Growth
- LUNR N/A
- IBRX N/A
- EPS
- LUNR N/A
- IBRX N/A
- Revenue
- LUNR $203,899,000.00
- IBRX $7,332,000.00
- Revenue This Year
- LUNR $193.65
- IBRX $2,359.81
- Revenue Next Year
- LUNR $57.06
- IBRX $808.10
- P/E Ratio
- LUNR N/A
- IBRX N/A
- Revenue Growth
- LUNR 134.51
- IBRX 1218.71
- 52 Week Low
- LUNR $3.15
- IBRX $2.28
- 52 Week High
- LUNR $24.95
- IBRX $10.53
- Technical
- Relative Strength Index (RSI)
- LUNR 44.35
- IBRX 52.26
- Support Level
- LUNR $18.44
- IBRX $3.35
- Resistance Level
- LUNR $22.40
- IBRX $4.27
- Average True Range (ATR)
- LUNR 1.86
- IBRX 0.31
- MACD
- LUNR -0.31
- IBRX 0.04
- Stochastic Oscillator
- LUNR 10.46
- IBRX 29.17
About LUNR Intuitive Machines Inc.
Intuitive Machines Inc is a space exploration, infrastructure, and services company. It is a diversified space company focused on space exploration. It supplies space products and services to support sustained robotic and human exploration to the Moon, Mars, and beyond. Its products and services are offered through its four business units: Lunar Access Services, Orbital Services, Lunar Data Services, and Space Products and Infrastructure.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.